Encyclopedia entry
ApoB testing
Apolipoprotein B (ApoB) is a protein attached to every atherogenic lipoprotein particle in the bloodstream: LDL, VLDL, IDL, and Lp(a). Measuring ApoB directly counts the number of these particles, which is what actually drives atherosclerotic cardiovascular disease. A more accurate risk biomarker than LDL cholesterol concentration alone. UK longevity clinics now include ApoB in standard baseline bloods; NHS lipid profiles typically still focus on LDL.
Why ApoB is better than LDL alone
LDL cholesterol measures the concentration of cholesterol in LDL particles. Two patients can have the same LDL value but different particle counts; the patient with more, smaller particles has higher cardiovascular risk. ApoB counts the particles directly. The American Heart Association and European Society of Cardiology both now position ApoB as the preferred metric where available; NICE in the UK is gradually moving the same direction but NHS lab provision remains LDL-dominant.
Reference ranges
- · Optimal for primary prevention: ApoB under 80 mg/dL.
- · Optimal for high-risk patients (existing CVD, diabetes, familial hypercholesterolaemia): ApoB under 65 mg/dL.
- · Borderline: 80 to 100 mg/dL.
- · High: above 100 mg/dL.
UK access
NHS testing of ApoB is uncommon outside specialist lipid clinics. Private testing via Medichecks, Randox, Thriva, and most UK longevity clinics costs £20 to £60 as part of a comprehensive lipid panel. UK longevity providers (Hooke, Echelon, Reliant) include ApoB in standard baseline bloods. Self-pay home test kits are also widely available.
What changes on GLP-1
GLP-1 weight loss reduces ApoB substantially in most patients, more than LDL alone would suggest. The mechanism includes both reduced hepatic VLDL production and direct effects on insulin sensitivity. Patients with elevated baseline ApoB often see meaningful reduction by month 6 of treatment, sometimes enabling reduction or discontinuation of statin therapy under prescriber supervision.